Time Series Clustering of T Cell Subsets Dissects Heterogeneity in Immune Reconstitution and Clinical Outcomes Among MUD-HCT Patients Receiving ATG or PTCy
Overview
Authors
Affiliations
Introduction: Anti-T-lymphocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy) prevent graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT), yet individual patients benefit differentially.
Methods: Given the sparse comparative data on the impact of cellular immune reconstitution in this setting, we studied flow cytometry and clinical outcomes in 339 recipients of 10/10 matched-unrelated donor (MUD) HCT using either ATG (n=304) or PTCy (n=35) for T cell manipulation along with a haploidentical PTCy control cohort (n=45). Longitudinal cellular immune reconstitution data were analyzed conventionally and with a data science approach using clustering with dynamic time warping to determine the similarity between time-series of T cell subsets.
Results: Consistent with published studies, no significant differences in clinical outcomes were observed at the cohort level between MUD-ATG and MUD-PTCy. However, cellular reconstitution revealed preferences for distinct T cell subpopulations associating with GVHD protection in each setting. Starting early after HCT, MUD-PTCy patients had higher regulatory T cell levels after HCT (p <0.0001), while MUD-ATG patients presented with higher levels of γδ T- or NKT cells (both p <0.0001). Time-series clustering further dissected the patient population's heterogeneity revealing distinct immune reconstitution clusters. Importantly, it identified phenotypes that reproducibly associated with impaired clinical outcomes within the same T cell manipulation platform. Exemplarily, patients with lower activated- and αβ T cell counts had significantly higher NRM (p=0.032) and relapse rates (p =0.01).
Discussion: The improved understanding of the heterogeneity of cellular reconstitution in MUD patients with T cell manipulation both at the cohort and individual level may support clinicians in managing HCT complications.
Choi E, Han J, Park H, Park H, Choi Y, Lee J Bone Marrow Transplant. 2024; 59(9):1329-1331.
PMID: 38977776 DOI: 10.1038/s41409-024-02364-6.
Nakamae H Front Immunol. 2024; 15:1403936.
PMID: 38903503 PMC: 11187280. DOI: 10.3389/fimmu.2024.1403936.
Huang J, Pan Z, Wang L, Zhang Z, Huang J, Jiang C Clin Exp Med. 2024; 24(1):22.
PMID: 38280072 PMC: 10821970. DOI: 10.1007/s10238-023-01270-3.